Cover Image
市場調查報告書

BioMarin Pharmaceutical Inc. : 產品平台分析

BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 240909
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
BioMarin Pharmaceutical Inc. : 產品平台分析 BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2016
出版日期: 2016年06月22日 內容資訊: 英文 60 Pages
簡介

BioMarin Pharmaceutical Inc. 是製造並銷售治療嚴重疾病或症狀用的創新醫藥品之生物製藥公司。

本報告提供BioMarin Pharmaceutical Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

BioMarin Pharmaceutical Inc.的基本資料

  • BioMarin Pharmaceutical Inc.概要
  • 主要資訊
  • 企業資料

BioMarin Pharmaceutical Inc.:R&D概要

  • 主要的治療範圍

BioMarin Pharmaceutical Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

BioMarin Pharmaceutical Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
    • 第0相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

BioMarin Pharmaceutical Inc.:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

BioMarin Pharmaceutical Inc.:藥物簡介

  • drisapersen
  • elosulfase alfa
  • sapropterin dihydrochloride
  • amifampridine phosphate
  • pegvaliase
  • reveglucosidase alfa
  • talazoparib
  • BMN-044
  • BMN-045
  • BMN-111
  • cerliponase alfa
  • BMN-053
  • RG-2833
  • Antisense RNAi Oligonucleotides to Activate Dysferlin for Dysferlinopathies
  • BMN-250
  • BMN-270
  • PRO-052
  • PRO-055
  • PRO-135
  • PRO-289
  • PROSPECT
  • RG-3250
  • Small Molecule for Sanfilippo Syndrome
  • Antisense RNAi Oligonucleotide for Rheumatoid Arthritis
  • RNAi Oligonucleotide for Bone Diseases
  • RNAi Oligonucleotide for Cancer
  • RNAi Oligonucleotide for Skin Diseases

BioMarin Pharmaceutical Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

BioMarin Pharmaceutical Inc.:最近的開發平台趨勢

BioMarin Pharmaceutical Inc.:暫停中的計劃

BioMarin Pharmaceutical Inc.:暫停中的計劃

BioMarin Pharmaceutical Inc.:企業發表

BioMarin Pharmaceutical Inc.:總公司和子公司的所在地

BioMarin Pharmaceutical Inc.:主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08070CDB

Summary

Global Markets Direct's, 'BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2016', provides an overview of the BioMarin Pharmaceutical Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by BioMarin Pharmaceutical Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of BioMarin Pharmaceutical Inc.
  • The report provides overview of BioMarin Pharmaceutical Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses BioMarin Pharmaceutical Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features BioMarin Pharmaceutical Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate BioMarin Pharmaceutical Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for BioMarin Pharmaceutical Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding BioMarin Pharmaceutical Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • BioMarin Pharmaceutical Inc. Snapshot
    • BioMarin Pharmaceutical Inc. Overview
    • Key Information
    • Key Facts
  • BioMarin Pharmaceutical Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • BioMarin Pharmaceutical Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • BioMarin Pharmaceutical Inc. - Pipeline Products Glance
    • BioMarin Pharmaceutical Inc. - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • BioMarin Pharmaceutical Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • BioMarin Pharmaceutical Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • BioMarin Pharmaceutical Inc. - Drug Profiles
    • amifampridine phosphate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegvaliase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • reveglucosidase alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cerliponase alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vosoritide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMN-250
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMN-270
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotides to Activate Dysferlin for Dysferlinopathies
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRO-052
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRO-055
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRO-135
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRO-289
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-3250
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Sanfilippo Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • BioMarin Pharmaceutical Inc. - Pipeline Analysis
    • BioMarin Pharmaceutical Inc. - Pipeline Products by Target
    • BioMarin Pharmaceutical Inc. - Pipeline Products by Route of Administration
    • BioMarin Pharmaceutical Inc. - Pipeline Products by Molecule Type
    • BioMarin Pharmaceutical Inc. - Pipeline Products by Mechanism of Action
  • BioMarin Pharmaceutical Inc. - Recent Pipeline Updates
  • BioMarin Pharmaceutical Inc. - Dormant Projects
  • BioMarin Pharmaceutical Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • BMN-044
      • BMN-045
      • BMN-053
      • drisapersen
  • BioMarin Pharmaceutical Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • BioMarin Pharmaceutical Inc. - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • BioMarin Pharmaceutical Inc., Key Information
  • BioMarin Pharmaceutical Inc., Key Facts
  • BioMarin Pharmaceutical Inc. - Pipeline by Indication, 2016
  • BioMarin Pharmaceutical Inc. - Pipeline by Stage of Development, 2016
  • BioMarin Pharmaceutical Inc. - Monotherapy Products in Pipeline, 2016
  • BioMarin Pharmaceutical Inc. - Out-Licensed Products in Pipeline, 2016
  • BioMarin Pharmaceutical Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • BioMarin Pharmaceutical Inc. - Filing rejected/Withdrawn, 2016
  • BioMarin Pharmaceutical Inc. - Phase III, 2016
  • BioMarin Pharmaceutical Inc. - Phase II, 2016
  • BioMarin Pharmaceutical Inc. - Phase I, 2016
  • BioMarin Pharmaceutical Inc. - Preclinical, 2016
  • BioMarin Pharmaceutical Inc. - Pipeline by Target, 2016
  • BioMarin Pharmaceutical Inc. - Pipeline by Route of Administration, 2016
  • BioMarin Pharmaceutical Inc. - Pipeline by Molecule Type, 2016
  • BioMarin Pharmaceutical Inc. - Pipeline Products by Mechanism of Action, 2016
  • BioMarin Pharmaceutical Inc. - Recent Pipeline Updates, 2016
  • BioMarin Pharmaceutical Inc. - Dormant Developmental Projects,2016
  • BioMarin Pharmaceutical Inc. - Discontinued Pipeline Products, 2016
  • BioMarin Pharmaceutical Inc., Other Locations
  • BioMarin Pharmaceutical Inc., Subsidiaries
  • BioMarin Pharmaceutical Inc., Key Manufacturing Facilities

List of Figures

  • BioMarin Pharmaceutical Inc. - Pipeline by Top 10 Indication, 2016
  • BioMarin Pharmaceutical Inc. - Pipeline by Stage of Development, 2016
  • BioMarin Pharmaceutical Inc. - Monotherapy Products in Pipeline, 2016
  • BioMarin Pharmaceutical Inc. - Out-Licensed Products in Pipeline, 2016
  • BioMarin Pharmaceutical Inc. - Pipeline by Top 10 Target, 2016
  • BioMarin Pharmaceutical Inc. - Pipeline by Route of Administration, 2016
  • BioMarin Pharmaceutical Inc. - Pipeline by Molecule Type, 2016
  • BioMarin Pharmaceutical Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top